Introduction
CA-NSI in children causes significant parental anxiety. The risk of HIV and hepatitis virus transmission following NSI in healthcare settings is well established. The risk of BBV transmission to a child from a CA-NSI is substantially less than from occupational exposure. Despite this, many clinical guidelines are based on occupational NSI.
SEARCH STRATEGY AND OUTCOME
Medline was searched using the Ovid interface (1946 to present/no limits set) using MeSH subject headings: (*needlestick injuries/ or *needles/ or *syringes/) and (*blood-borne pathogens/ or (*hiv infections/ or *acquired immunodeficiency syndrome/ or *hiv seropositivity/) or (*hepatitis/ or *hepatitis, viral, human/ or *hepatitis b/ or *hepatitis c/) or (community. mp. or *community-acquired infections/ or *environmental exposure/)). No age limits were imposed for reported cases of BBV transmission from CA-NSI, on the basis that confirmed transmission at any age would support the theoretical possibility of transmission in children. Only papers addressing non-healthcare-related CA-NSI were included. Cross-sectional studies with no longitudinal follow-up and those reporting exclusively BBV transmission from injecting drug use were excluded. The search date was 11 May 2014.
The Medline search retrieved 1100 publications, of which 16 were relevant. Search of Embase via the Ovid interface (1974-present) using the same search strategy retrieved 918 publications and identified 1 additional relevant paper. The 17 relevant publications were hand-searched for further references and 4 further relevant publications were found. Search of the Cochrane Library database retrieved no relevant reviews. The final 21 included studies are summarised in tables 1 and 2. When the original publication provided insufficient information, authors were contacted for further details.
COMMENTARY
Of the 21 studies, there were 17 observational studies (table 1) and 4 reports describing a total of 5 cases (table 2) . Repeated attempts to contact the authors of one observational study to clarify the findings were unsuccessful and that paper was excluded from further analysis. 1 The remaining observational studies were heterogeneous in study design (nine retrospective, 2-10 six prospective, [11] [12] [13] [14] [15] [16] one mixed 17 ) and completeness of reported outcomes, including the age of cases. Some studies included CA-NSI alongside other exposures, and where possible, the other exposures were excluded from our review. Some did not distinguish between exposures in reporting results (none of these studies documented a BBV transmission). For most studies, there was a high rate of loss to follow-up. Serological results for hepatitis B (HBV), hepatitis C virus (HCV) and HIV were inconsistently reported and available for all three in only a few studies.
Between 1987 and 2011, 1565 cases of CA-NSI were reported in the 16 observational studies. HIV postexposure prophylaxis (PEP) was recommended in 198 cases. Where reported, adherence to prescribed HIV PEP was generally poor. Of the 1565 cases, 1 unvaccinated adult caring for a relative with chronic HBV infection, in a country with a relatively high HBV infection rate and without routine HBV vaccination, developed evidence of HBV infection in the 8 weeks after sustaining a NSI while disposing of an intravenous needle and after declining postexposure HBV immunoglobulin and vaccination. There were no other cases of HBV seroconversion (serology reported for 604 patients), HCV seroconversion (423 patients) or HIV seroconversion (995 patients). There were no cases of virus transmission in children or adolescents.
Five cases of BBV transmission attributed to CA-NSI were reported in the four case reports, including two cases of HBV 18 19 and three of HCV. 20 21 In each case, the possibility of viral transmission by an alternative route could not be ruled out. There were no reports of HIV transmission. Only one of the five cases was a child and occurred following a CA-NSI from a needle discarded by a neighbour with known HBV and HIV infection. The child's immunisation status was not reported, and he was not given postexposure HBV immunoglobulin or vaccination. The remaining four cases occurred in adults, two of whom were in high-risk occupations. For the single adult case of HBV infection, immunisation status was not reported and he did not receive appropriate postexposure HBV immunoglobulin or vaccination. Each of the five patients developed hepatitis. In the three adults with HCV transmission, HCV antibody was detected from 3 months post NSI. One adult with HBV cleared the virus, and one adult with HCV had successful interferon-based treatment. The 4-year-old boy had unsuccessful treatment and developed chronic hepatitis.
Occupational studies provide estimates of the risk associated with NSI. Meta-analyses report mean risk rates of 0.23% for HIV, 22 0.75% for HCV 23 and 23-37% (HBeAg-negative source) or 37-62% (HBeAg-positive source) for HBV. 24 However, for HBV, vaccination or adequate PEP (vaccine±immunoglobulin) confers near-total protection. Risk for BBV transmission in the healthcare setting is highest with deep injection of a large inoculum (large volume, high viral load) as is more likely to occur in association with a large-gauge hollow-bore needle. 25 26 Extrapolated to the community setting, deep injury with a largegauge hollow-bore needle, visibly stained or filled with blood, sustained minutes following use (such as might occur in a household with a known infected drug user or in a deliberate assault), would be expected to carry a similar risk. However, most episodes of CA-NSI in children, such as in our scenario, are not associated with these risk factors. While study findings of viral persistence give cause for concern, the same studies indicate that under usual conditions of needle use in the community (smallgauge, low-void-volume syringes) and subsequent environmental exposure (time, heat, drying, humidity, chemicals), infectivity is markedly and rapidly reduced. [27] [28] [29] [30] [31] [32] [33] [34] [35] This risk analysis assumes the source needle user is infected, whereas BBV rates among people who inject drugs actually vary markedly worldwide and are lower in developed countries with universal HBV vaccination and needle exchange. [36] [37] [38] Very low risk of infection 
